Table 3 Characteristics of dendritic-cell-based vaccine studies
Author | Year | Country | Type of study | Host | Vaccine immunogen content | Vaccine dose | Route | Prescribed number | Laboratory method | Main findings |
|---|---|---|---|---|---|---|---|---|---|---|
Sagar, Divya | 2014 | USA | in vivo | Transgenic hybrid mice generated from an intercross between HLA-A2.1 and DTR transgenic mice / HLA-A2.1 transgenic mice / DTR transgenic mice the last two types were used to produce the hybrid mice | Tax(11–19) epitope | 100 μg | ID/SC | once | PCR/ELISA/MILLIPLEX magnetic bead assay | reduced proliferation of CD8 + splenocytes from Tax 11–19 immunized DC depleted mice, higher frequency of Tax 11- 19-specific cells with adjuvant usage, Tax 11–19 epitope as a potential candidate for a DC-based anti-HTLV-1 vaccine |
Suehiro, Youko | 2015 | Japan | human | human | autologous dendritic cells (DCs) pulsed with Tax peptides corresponding to the CTL epitopes | \(5\times10^6\)Â | SC | three times at 2-week intervals | PCR | Tax specific CTL response, partial remission in 1 patient, complete remission in 1 patient, maintaining remission status without any additional chemotherapy, progressive disease in 1 patient, |
Ando, S | 2017 | Japan | in vivo | Three- to six-week-old female rats (F344/N Jcl-rnu/ +) | HTLV-1 Tax(180–188)-specific CTL epitope-pulsed dendritic cell therapy | \(1\times10^6\) cells | SC | once a week for 3 wk into rats | PCR, ELISA, Flow cytometry, | monocyte-derived DCs capacity to stimulate CMV-specific autologous CTLs in vitro, peptide-pulsed DC immunotherapy will be useful to induce functional HTLV-1–specific CTLs and decrease PVL in infected individuals with high PVL and impaired HTLV-1–specific CTL responses, therby reducing the risk of the development of ATL |